JP4989648B2 - 抗癌剤として有用なイルジン類似体 - Google Patents

抗癌剤として有用なイルジン類似体 Download PDF

Info

Publication number
JP4989648B2
JP4989648B2 JP2008525225A JP2008525225A JP4989648B2 JP 4989648 B2 JP4989648 B2 JP 4989648B2 JP 2008525225 A JP2008525225 A JP 2008525225A JP 2008525225 A JP2008525225 A JP 2008525225A JP 4989648 B2 JP4989648 B2 JP 4989648B2
Authority
JP
Japan
Prior art keywords
compound according
alkyl
cancer
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008525225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009503110A5 (https=
JP2009503110A (ja
Inventor
トレバー シー． マクモリス，
マイケル ジェイ． ケルナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2009503110A publication Critical patent/JP2009503110A/ja
Publication of JP2009503110A5 publication Critical patent/JP2009503110A5/ja
Application granted granted Critical
Publication of JP4989648B2 publication Critical patent/JP4989648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008525225A 2005-08-03 2006-08-03 抗癌剤として有用なイルジン類似体 Active JP4989648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70501705P 2005-08-03 2005-08-03
US60/705,017 2005-08-03
PCT/US2006/030439 WO2007019308A2 (en) 2005-08-03 2006-08-03 Illudin analogs useful as anticancer agents

Publications (3)

Publication Number Publication Date
JP2009503110A JP2009503110A (ja) 2009-01-29
JP2009503110A5 JP2009503110A5 (https=) 2009-09-24
JP4989648B2 true JP4989648B2 (ja) 2012-08-01

Family

ID=37727922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525225A Active JP4989648B2 (ja) 2005-08-03 2006-08-03 抗癌剤として有用なイルジン類似体

Country Status (5)

Country Link
US (1) US7655695B2 (https=)
EP (1) EP1909783B1 (https=)
JP (1) JP4989648B2 (https=)
AT (1) ATE527998T1 (https=)
WO (1) WO2007019308A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
WO2015157578A2 (en) 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
US10285955B2 (en) 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
US11135182B2 (en) 2014-04-10 2021-10-05 Af Chemicals, Llc Affinity medicant conjugates
CN112804995B (zh) * 2018-09-04 2025-11-04 蓝腾制药公司 隐杯伞素类似物、其应用及其合成方法
EP3863615A4 (en) * 2018-10-14 2022-08-03 Lantern Pharma Inc. METHODS OF TREATMENT OF CANCERS WITH SOLID TUMORS USING ILLUDINS AND BIOMARKERS
EP4524569A3 (en) 2018-12-11 2025-06-18 AF Chemical LLC Methods, compositions and devices for treating cancer with illudofulvenes
US11591295B2 (en) 2019-11-25 2023-02-28 Af Chemicals Llc Affinity illudofulvene conjugates
US20230181499A1 (en) * 2020-04-10 2023-06-15 Lantern Pharma Inc. Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer
WO2021226592A1 (en) * 2020-05-08 2021-11-11 Lantern Pharma Inc. Method for treating pancreatic cancer
JP2024502001A (ja) 2020-12-29 2024-01-17 ランタン ファルマ インコーポレイテッド ラブドイド腫瘍を治療する方法
KR20230130044A (ko) * 2021-01-08 2023-09-11 랜턴 파마 인코포레이티드 일루딘 또는 하이드록시우레아메틸 아실풀벤을 사용한뇌 전이 및 cns 전이의 치료
AU2022256540A1 (en) * 2021-04-12 2023-11-02 Lantern Pharma Inc. Method for treating lung cancer and non-small cell lung cancer
CN117320704A (zh) * 2021-05-03 2023-12-29 蓝腾制药公司 血癌的治疗方法
AU2022317139A1 (en) * 2021-07-29 2024-03-14 Lantern Pharma Inc. Treating cancers with combinations of spironolactone and acylfulvenes
EP4376822A4 (en) * 2021-07-29 2025-09-17 Lantern Pharma Inc TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS
EP4719371A2 (en) * 2023-05-30 2026-04-08 Lantern Pharma Inc. Treating cancers with combinations of anti-cd20 antibody and acylfulvenes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459157A (en) * 1891-09-08 Running-gear for vehicles
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
JPS62234040A (ja) 1986-04-02 1987-10-14 Kyowa Hakko Kogyo Co Ltd Ｄｃ１０４３物質
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE68913995T2 (de) 1989-09-27 1994-08-25 Mo Ni Skij I Glaznych Boleznej Zusammensetzung zur behandlung progressiver myopie.
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
US5439936A (en) 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
EP0565519B1 (en) 1989-10-03 1996-08-28 The Regents Of The University Of California Illudin analogs as anti-tumor agents
EP0450761A1 (en) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
KR900016822A (ko) * 1990-04-20 1990-11-14 하라 레이노스께 슬라이드 프로젝터
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
DZ1773A1 (fr) 1993-04-27 2002-02-17 Smithkline Beecham Corp Antagonistes de récepteurs d'endothéline.
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
WO1996008466A1 (en) * 1994-09-12 1996-03-21 Takeda Chemical Industries, Ltd. Benzocycloalkene compounds, their production and use
JP3908798B2 (ja) * 1994-09-12 2007-04-25 武田薬品工業株式会社 ベンゾシクロアルケン類、その製造法および剤
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents

Also Published As

Publication number Publication date
US20080306147A1 (en) 2008-12-11
ATE527998T1 (de) 2011-10-15
US7655695B2 (en) 2010-02-02
EP1909783A2 (en) 2008-04-16
WO2007019308A2 (en) 2007-02-15
EP1909783A4 (en) 2010-08-04
EP1909783B1 (en) 2011-10-12
JP2009503110A (ja) 2009-01-29
WO2007019308A3 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
JP4989648B2 (ja) 抗癌剤として有用なイルジン類似体
EP3743069B1 (en) Bcl-2 proteins degraders for cancer treatment
EP3395821A1 (en) Antitumoral compounds
EP2263694A1 (en) Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
EP1267854B1 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
KR20010006402A (ko) 친핵체 치환 엑테이나시딘 및 ｎ-옥시드 엑테이나시딘
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
CZ20004183A3 (en) Metabolites of ecteinascidine 743
JP2021100982A (ja) Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物
JP2016535014A (ja) がんの処置のための医薬の組合せ
HUP0100927A2 (hu) Daganatellenes hatású helyettesített indánszármazékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP3248981B1 (en) C14-hydroxyl esterified amino acid derivatives of triptolide, and preparation method and use thereof
WO2008007367A1 (en) Combination methods of treating cancer
EP3126356B1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
US20150342909A1 (en) Therapeutic compounds and methods
CN101489540A (zh) 钌(ⅱ)化合物
CN115697317A (zh) Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
US20240109925A1 (en) Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea
DE202015009594U1 (de) Neue Dimere von Cytidin-Derivaten
KR101220331B1 (ko) 종양 억제 활성을 갖는 화합물
KR102567944B1 (ko) 신규 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
DE69119199T2 (de) Methode zur Hemmung von Tumorwachstum unter Verwendung von Xanthocillin-X-dimethylether
KR20210044521A (ko) 오토탁신 또는 리소포스파티드산에 의해 유도된 암세포 침윤을 억제하는 항암용 약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120424

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120427

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4989648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250